Does atazanavir cause lipodystrophy?

J HIV Ther. 2004 May;9(2):41-4.

Abstract

Atazanavir is a once-a-day non-pepsidic inhibitor of HIV protease which is licensed for use in the UK and the USA. One of its major advantages is that it does not produce lipid abnormalities in patients who receive it. This feature has been widely interpreted as implying that in the future there will be no abnormalities associated with fat redistribution when the drug is administered. This article explores that view.

Publication types

  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active / adverse effects
  • Antiretroviral Therapy, Highly Active / methods
  • Atazanavir Sulfate
  • HIV Infections / complications
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • HIV-Associated Lipodystrophy Syndrome / chemically induced*
  • HIV-Associated Lipodystrophy Syndrome / virology
  • Humans
  • Oligopeptides / adverse effects*
  • Oligopeptides / therapeutic use
  • Pyridines / adverse effects*
  • Pyridines / therapeutic use

Substances

  • HIV Protease Inhibitors
  • Oligopeptides
  • Pyridines
  • Atazanavir Sulfate